Last updated: February 16, 2026
What is the drug with NDC 78206-0153?
The drug with NDC 78206-0153 is Revlimid (lenalidomide), marketed by Celgene (a Bristol Myers Squibb company). It is primarily used for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma.
What is the current market status for Revlimid (lenalidomide)?
Revlimid is among the highest-revenue drugs globally. In 2022, Bristol Myers Squibb reported global sales exceeding $12 billion, with Revlimid accounting for over 70% of that figure. The drug gained approval from the FDA in 2005[1].
Revlimid's patent exclusivity was scheduled to expire in 2026 in the U.S., but legal challenges and patent extensions prolong market dominance. Biosimilars entered the European markets in 2022, reducing prices there.
What are the key factors impacting Revlimid's market?
Patent and Regulatory Environment
- Patent status: U.S. patents expected to expire in 2026, though extensions may delay generic entry. European patent expiry was 2022.
- Legal challenges: Multiple patent lawsuits and patent term extensions have so far allowed continued exclusivity.
- Regulatory approvals: Approved for multiple indications, with ongoing studies for additional uses.
Market Dynamics
- Market size: Estimated at over $12 billion globally in 2022.
- Key markets: U.S., European Union, China.
- Pricing: U.S. prices are high; retail prices can surpass $15,000 per month per patient.
- Patents and biosimilars: European biosimilars have eroded market share; US biosimilar approvals are pending or recent.
Competitive Landscape
- Late-stage pipeline drugs and biosimilars threaten Revlimid’s dominance.
- Other therapies, such as Pomalyst and newer immunotherapies, impact sales.
What are the pricing trends for Revlimid?
Current Pricing
- Monthly treatment cost: ~$15,000 in the U.S.
- Annual treatment cost: approximately $180,000 per patient.
Historical Trends
- Prices increased steadily from approval in 2005 through 2019.
- Price stabilization or slight reductions observed in Europe post-biosimilar entry.
Future Price Projections
- Until 2025: Prices will likely remain stable, with slight declines driven by biosimilar competition and negotiated discounts.
- Post-2026: Prices in the U.S. could decline by 50% or more if biosimilar market penetration gains momentum.
- Biosimilar impact: Sales may shift from original to biosimilars, which are priced 20-40% lower.
What are the projections for Revlimid’s market through 2030?
| Year |
Estimated Global Sales |
Price per Cycle |
Market Share (assuming biosimilars’ entry) |
| 2023 |
$11.5-$12 billion |
$15,000/month |
90% (pre-biosimilar) |
| 2025 |
$9-$11 billion |
Stabilizing |
85% |
| 2027 |
$6-$8 billion |
Declining with biosimilar |
60-70% (biosimilars enter) |
| 2030 |
$4-$6 billion |
Lower prices, biosimilar dominance |
30-50% (biosimilar share) |
The decline risk peaks post-2026, with the entry of biosimilars expected to cut revenues significantly. The rate of market penetration will depend on patent litigation outcomes, biosimilar pricing strategies, and clinicians' adoption.
What are the key risks for long-term pricing and market share?
- Patent expiration and legal disputes could accelerate biosimilar entry.
- Regulatory approvals for competing therapies might reduce Revlimid sales.
- Pricing pressures from payers and health systems may necessitate discounts.
- Pipeline developments: Any approved competitor drug with superior efficacy or fewer side effects could displace Revlimid.
Final considerations
Revlimid remains a high-revenue drug with a dominant market position through 2025. Post-2026, significant declines are expected absent new indications, improved formulations, or extended patent protections. Investors and stakeholders should monitor legal developments, biosimilar approval timelines, and emerging competitors.
Key Takeaways
- Revlimid’s 2022 global sales exceeded $12 billion, primarily in oncology.
- Patent expiry expected in 2026 could lead to biosimilar competition, sharply reducing prices.
- Prices are around $15,000 per month per patient in the U.S., with gradual declines projected post-2026.
- Biosimilar entry in Europe in 2022 led to price erosion; U.S. biosimilar approvals are pending.
- Market share is likely to decrease significantly by 2030, influenced by biosimilars and new therapies.
FAQs
1. When will biosimilars for Revlimid be available in the U.S.?
Pending FDA approvals, biosimilars could reach the U.S. market as early as 2025 or 2026, depending on patent litigation and regulatory timelines.
2. How much will biosimilars reduce Revlimid prices?
Biosimilars are expected to be priced 20-40% lower than the originator, leading to potential price drops of up to 50% in total revenue.
3. What new indications could extend Revlimid’s market life?
Research into additional cancer types and combination therapies could extend the drug’s approved use and sustain revenues.
4. How do patent extensions impact Revlimid’s market outlook?
Extensions can delay biosimilar entry, maintaining higher prices and revenues past initial patent expiry dates.
5. What alternatives exist if Revlimid’s market declines?
Pomalyst, newer immunotherapies, and treatment combinations hold potential to replace or reduce reliance on Revlimid in key indications.
Cited Sources:
[1] Bristol Myers Squibb 2022 Annual Report.
